What Is Semaglutide? Uses, Benefits, Safety, FDA Status, and Evidence

Medical review note: This article is for educational purposes only and does not provide medical advice. Semaglutide is an FDA-approved prescription medication for specific uses, but unapproved semaglutide products sold online or labeled as “research use only” may carry serious safety, quality, and legal risks.

Quick answer

Semaglutide is a glucagon-like peptide-1 receptor agonist, usually called a GLP-1 receptor agonist. It helps regulate blood sugar, appetite, satiety, gastric emptying, and body weight. In the United States, semaglutide is sold under several FDA-approved brand names, including Ozempic for type 2 diabetes, Wegovy for chronic weight management and cardiovascular risk reduction in certain adults, and Rybelsus as an oral semaglutide tablet for type 2 diabetes. Semaglutide has strong human clinical evidence, but it can cause gastrointestinal side effects, carries a boxed warning related to thyroid C-cell tumors observed in rodents, and should not be confused with unapproved online or research-use versions.

Key facts about Semaglutide

Question	Answer
What is semaglutide?	A GLP-1 receptor agonist used in FDA-approved medications for metabolic disease.
Brand names	Ozempic, Wegovy, Rybelsus.
Drug class	GLP-1 receptor agonist.
Main mechanism	Mimics GLP-1 activity to influence insulin secretion, glucagon regulation, appetite, satiety, gastric emptying, and body weight.
FDA-approved?	Yes, under specific brand names and indications.
Ozempic indication	Type 2 diabetes, with additional cardiovascular and kidney-related indications in certain adults.
Wegovy indication	Chronic weight management and cardiovascular risk reduction in certain adults with obesity or overweight.
Rybelsus indication	Oral semaglutide for type 2 diabetes.
Human evidence level	Strong human clinical evidence for approved uses.
Common side effects	Nausea, vomiting, diarrhea, constipation, abdominal pain, indigestion, and decreased appetite.
Boxed warning	Risk of thyroid C-cell tumors observed in rodents; human relevance is unknown.
Sports status	GLP-1 drugs are not currently prohibited by WADA, but semaglutide has been included in WADA monitoring.
Main safety concern	Side effects, contraindications, pancreatitis/gallbladder warnings, and unsafe unapproved or counterfeit products.

What is semaglutide?

Semaglutide is a prescription GLP-1 receptor agonist. GLP-1 stands for glucagon-like peptide-1, an incretin hormone involved in glucose regulation, appetite, digestion, and body-weight control.

Semaglutide is not one single consumer product. It is the active ingredient used in several FDA-approved medications:

Brand	Active ingredient	Main FDA-approved use
Ozempic	Semaglutide	Type 2 diabetes and certain cardiovascular/kidney risk indications.
Wegovy	Semaglutide	Chronic weight management and cardiovascular risk reduction in certain adults.
Rybelsus	Semaglutide	Oral tablet for type 2 diabetes.

The FDA-approved Ozempic prescribing information identifies Ozempic as semaglutide injection for type 2 diabetes and includes additional indications related to cardiovascular and kidney risk in certain adults with type 2 diabetes.

The FDA-approved Wegovy prescribing information identifies Wegovy as semaglutide injection used for chronic weight management and certain cardiovascular risk-reduction indications.

The FDA-approved Rybelsus prescribing information identifies Rybelsus as oral semaglutide tablets.

How does semaglutide work?

Semaglutide activates GLP-1 receptors. GLP-1 receptor activity can help:

Increase insulin secretion when blood glucose is elevated
Reduce inappropriate glucagon secretion
Slow gastric emptying
Increase satiety
Reduce appetite
Support weight loss in appropriate patients

That mechanism explains why semaglutide is used in both diabetes and weight-management contexts.

But the mechanism is not the whole story. Semaglutide matters because it has been tested in large human clinical trials and has FDA-approved indications. That separates it from many experimental peptides that are marketed online despite limited human evidence.

What is semaglutide used for?

Semaglutide has approved medical uses and common market-driven claims. These should not be treated the same.

Use	Evidence level	What is known	What is not known
Type 2 diabetes	Strong human evidence	Ozempic and Rybelsus are FDA-approved semaglutide products for adults with type 2 diabetes.	Individual outcomes depend on medical history, adherence, tolerability, and clinician supervision.
Chronic weight management	Strong human evidence	Wegovy is FDA-approved for chronic weight management in adults and certain adolescents with obesity, and some adults with overweight and weight-related conditions.	Long-term maintenance usually requires continued treatment and lifestyle support.
Cardiovascular risk reduction	Strong human evidence for specific groups	Wegovy is FDA-approved to reduce major cardiovascular event risk in adults with established cardiovascular disease and obesity or overweight.	It is not a universal cardiovascular medication for all patients.
Kidney-risk reduction in type 2 diabetes	FDA-approved for specific group	Ozempic has an indication to reduce sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.	It is not a general kidney medication for all patients.
Cosmetic weight loss	Not an approved framing	Some people seek semaglutide outside clear medical indications.	Risk-benefit should be assessed by a clinician.
Research-use semaglutide	Unsafe / unapproved	FDA warns against unapproved GLP-1 products sold directly to consumers.	Quality, sterility, dosing, and authenticity may be unknown.
Performance enhancement	Not a supported use	GLP-1 drugs are not currently prohibited in sport, but they are being monitored.	Athletes should verify current anti-doping rules and avoid unapproved products.

What does the research show?

Human evidence for weight loss

Semaglutide has strong human clinical evidence for weight loss in adults with obesity or overweight.

In the STEP 1 trial published in the New England Journal of Medicine, once-weekly semaglutide 2.4 mg plus lifestyle intervention was associated with substantial body-weight reduction compared with placebo in adults with overweight or obesity.

A PubMed summary of the STEP 1 trial states that once-weekly semaglutide 2.4 mg plus lifestyle intervention was associated with sustained, clinically relevant body-weight reduction.

The practical interpretation:

Semaglutide has strong human evidence for weight loss in the populations studied. It is not merely a preclinical or experimental peptide claim.

Human evidence for type 2 diabetes

Semaglutide has also been studied extensively for type 2 diabetes. Ozempic and Rybelsus are FDA-approved semaglutide products for adults with type 2 diabetes.

The Ozempic prescribing information identifies semaglutide injection as a once-weekly medication used with diet and exercise to improve glycemic control in adults with type 2 diabetes.

The practical interpretation:

Semaglutide has strong evidence for improving glycemic control in type 2 diabetes, and that is why Ozempic and Rybelsus are FDA-approved for that category.

Human evidence for cardiovascular risk reduction

Semaglutide also has cardiovascular-risk-related evidence and FDA-approved uses for specific populations.

The FDA announced in 2024 that Wegovy was approved to reduce the risk of serious heart problems in adults with cardiovascular disease and either obesity or overweight.

The practical interpretation:

Semaglutide is not only a diabetes or weight-loss drug. Under the Wegovy label, it also has an FDA-approved role in reducing major cardiovascular event risk in a specific adult population.

Human evidence for weight regain after stopping

Semaglutide is effective, but stopping treatment can lead to weight regain.

A PubMed-indexed follow-up analysis reported that one year after withdrawal of once-weekly semaglutide 2.4 mg and lifestyle intervention, participants regained a large portion of their prior weight loss.

The practical interpretation:

Semaglutide should not be understood as a short-term “quick fix.” For many patients, long-term benefit may require ongoing treatment, lifestyle support, and medical supervision.

Evidence summary

Claim	Evidence verdict	Explanation
“Semaglutide helps lower blood sugar in type 2 diabetes.”	Supported	Ozempic and Rybelsus are FDA-approved semaglutide products for type 2 diabetes.
“Semaglutide causes significant weight loss.”	Supported	Wegovy is FDA-approved for chronic weight management, and STEP trials showed clinically meaningful weight loss.
“Semaglutide reduces cardiovascular risk.”	Supported for specific groups	Wegovy is FDA-approved to reduce major cardiovascular event risk in adults with established cardiovascular disease and obesity or overweight.
“Semaglutide protects kidney outcomes.”	Supported for specific group	Ozempic has an indication related to kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
“Semaglutide is the same thing as BPC-157 or CJC-1295.”	False	Semaglutide is an FDA-approved GLP-1 receptor agonist, not an experimental repair peptide or growth-hormone secretagogue.
“Compounded semaglutide is the same as Ozempic or Wegovy.”	Misleading	FDA-approved products have specific manufacturing, quality, labeling, and prescribing controls.
“Semaglutide is risk-free.”	False	It can cause side effects and has warnings, contraindications, and safety considerations.
“Semaglutide is banned in sports.”	Not currently	USADA says GLP-1 drugs are not prohibited, but WADA is monitoring GLP-1 agonists.
“Research-use semaglutide is safe if the seller says it is pure.”	Unsupported	FDA warns against unapproved GLP-1 products sold directly to consumers, including those falsely labeled for research use.

Is semaglutide FDA-approved?

Yes, but only under specific FDA-approved products and indications.

The Ozempic prescribing information lists Ozempic as semaglutide injection for adults with type 2 diabetes, including glycemic control and certain cardiovascular and kidney-risk-related indications.

The Wegovy prescribing information lists Wegovy as semaglutide injection for chronic weight management and cardiovascular risk reduction in certain adults.

The Rybelsus prescribing information lists Rybelsus as oral semaglutide tablets for adults with type 2 diabetes.

The key distinction:

Semaglutide is FDA-approved when used as an approved prescription product for approved indications. Unapproved semaglutide products sold online, compounded without proper legal basis, or labeled as “research use only” are not the same as FDA-approved Ozempic, Wegovy, or Rybelsus.

Is semaglutide legal?

Semaglutide is legal when prescribed and dispensed as an FDA-approved medication for appropriate medical use.

The problem is the gray market.

The FDA warns consumers not to purchase unapproved GLP-1 products, including unapproved drugs containing semaglutide, tirzepatide, or retatrutide that are falsely labeled “for research purposes” or “not for human consumption” while being sold directly to consumers with dosing instructions.

The blunt version:

Prescription semaglutide from a legitimate pharmacy is different from unapproved semaglutide sold online as a peptide, research chemical, or knockoff weight-loss product.

Is semaglutide banned in sports?

Semaglutide and GLP-1 medications are not currently prohibited in sport, according to USADA’s GLP-1 guidance. However, WADA is monitoring and evaluating GLP-1 agonist use by athletes.

The USADA GLP-1 athlete guide says GLP-1s are not prohibited in sport, but athletes should be aware that many unapproved GLP-1 products carry significant safety risks.

USADA’s 2024 WADA Prohibited List update also states that semaglutide was added to WADA’s monitoring program to examine prevalence of use in sport. Substances in the monitoring program are not prohibited.

For athletes, the practical advice is:

Do not use unapproved semaglutide products, verify the current WADA status, and only use prescription medications under appropriate medical supervision.

Safety and side effects

Semaglutide has real clinical evidence, but it also has real safety considerations.

Common side effects may include:

Nausea
Vomiting
Diarrhea
Constipation
Abdominal pain
Indigestion
Decreased appetite
Injection-site reactions for injectable products

The FDA-approved labels for semaglutide products include a boxed warning about thyroid C-cell tumors observed in rodents. The Ozempic prescribing information states that semaglutide caused thyroid C-cell tumors in rodents and that it is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans.

Important safety considerations may include:

Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2
Pancreatitis risk warnings
Gallbladder disease warnings
Gastrointestinal side effects
Dehydration risk from vomiting or diarrhea
Hypoglycemia risk when used with insulin or insulin secretagogues
Pregnancy considerations
Product-quality risks from unapproved sources

A serious evaluation of semaglutide should separate the risk of the FDA-approved medication from the risk of counterfeit, compounded, or unapproved versions.

Semaglutide vs similar drugs and peptides

Compound	Category	Main difference
Semaglutide	GLP-1 receptor agonist	FDA-approved under Ozempic, Wegovy, and Rybelsus for specific metabolic indications.
Tirzepatide	Dual GIP/GLP-1 receptor agonist	Activates both GIP and GLP-1 pathways; sold as Mounjaro and Zepbound.
Retatrutide	Triple GIP/GLP-1/glucagon receptor agonist	Investigational, not FDA-approved as of this writing.
Liraglutide	GLP-1 receptor agonist	Older GLP-1 medication, usually injected daily.
BPC-157	Experimental repair peptide	Not FDA-approved, mostly preclinical tissue-repair evidence.
CJC-1295	GHRH analog	Growth-hormone-related peptide, not a metabolic incretin drug.

The key distinction:

Semaglutide is not a generic wellness peptide. It is a clinically studied, FDA-approved GLP-1 receptor agonist when used as Ozempic, Wegovy, or Rybelsus for approved indications.

Why is semaglutide sold as “research use only”?

Some online sellers use “research use only” language to sell unapproved semaglutide or semaglutide-like products directly to consumers. This is a red flag.

The FDA has specifically warned about unapproved GLP-1 drugs containing semaglutide that are falsely labeled for research use or not for human consumption while being sold to consumers with dosing instructions.

A serious reader should understand this distinction:

Product type	What it means
Ozempic	FDA-approved semaglutide injection for type 2 diabetes and certain related risk-reduction indications.
Wegovy	FDA-approved semaglutide injection for chronic weight management and cardiovascular risk reduction in certain adults.
Rybelsus	FDA-approved oral semaglutide tablet for type 2 diabetes.
Compounded semaglutide	May be legal only in limited circumstances; not the same as FDA-approved products.
Research-use semaglutide	Not an FDA-approved consumer therapeutic product.
Online peptide semaglutide	High risk for quality, sterility, dosing, and authenticity problems.

How to evaluate semaglutide claims online

Claim	What to verify
“FDA-approved semaglutide”	Is it actually Ozempic, Wegovy, or Rybelsus, or an unapproved product using the same active ingredient name?
“Compounded semaglutide”	Is there a valid prescription, legal compounding basis, and legitimate licensed pharmacy?
“Research use only”	This does not mean safe, approved, or appropriate for human use.
“Same as Wegovy”	FDA-approved Wegovy has specific manufacturing, quality, labeling, and prescribing controls.
“No side effects”	False. FDA-approved labels list common side effects and serious warnings.
“Better than tirzepatide”	Depends on endpoint, patient population, dose, tolerability, and trial design.
“Safe for athletes”	GLP-1s are not currently prohibited, but athletes should verify current rules and avoid unapproved products.
“Cheap semaglutide online”	High risk. FDA warns unapproved GLP-1 products may be of unknown quality and harmful.

Bottom line

Semaglutide is a clinically proven, FDA-approved GLP-1 receptor agonist when used as Ozempic, Wegovy, or Rybelsus for approved indications. It has strong human evidence for type 2 diabetes and chronic weight management, and Wegovy also has an FDA-approved role in cardiovascular risk reduction for certain adults with cardiovascular disease and obesity or overweight.

The most defensible conclusion is:

Semaglutide is one of the best-supported medications in the peptide-related metabolic category, but it should be treated as a prescription drug, not a casual wellness peptide. Readers should avoid unapproved online semaglutide, research-use products, and knockoffs that are not FDA-approved Ozempic, Wegovy, or Rybelsus.

FAQ

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist used in FDA-approved medications including Ozempic, Wegovy, and Rybelsus. It helps regulate blood sugar, appetite, satiety, gastric emptying, and body weight.

What does semaglutide do?

Semaglutide activates GLP-1 receptors. This can help improve insulin secretion when blood glucose is elevated, reduce inappropriate glucagon activity, slow gastric emptying, increase fullness, reduce appetite, and support weight loss in appropriate patients.

Is semaglutide FDA-approved?

Yes. Semaglutide is FDA-approved under Ozempic, Wegovy, and Rybelsus for specific indications, including type 2 diabetes, chronic weight management, and cardiovascular risk reduction in certain adults.

Is semaglutide the same as Ozempic?

Ozempic is a brand-name FDA-approved semaglutide injection used for type 2 diabetes and certain cardiovascular and kidney-risk-related indications. Semaglutide is the active ingredient.

Is semaglutide the same as Wegovy?

Wegovy is a brand-name FDA-approved semaglutide medication used for chronic weight management and cardiovascular risk reduction in certain adults. Semaglutide is the active ingredient.

Is semaglutide the same as Rybelsus?

Rybelsus is a brand-name FDA-approved oral semaglutide tablet used for adults with type 2 diabetes. Semaglutide is the active ingredient.

Is semaglutide safe?

Semaglutide is FDA-approved for specific uses but is not risk-free. It can cause gastrointestinal side effects and carries a boxed warning related to thyroid C-cell tumors observed in rodents.

Does semaglutide work for weight loss?

Yes. Semaglutide has strong human clinical evidence for weight loss in adults with obesity or overweight, and Wegovy is FDA-approved for chronic weight management.

Is semaglutide legal?

Semaglutide is legal when prescribed and dispensed as an FDA-approved medication. Unapproved online semaglutide, research-use products, and knockoffs are different and may carry legal, safety, and quality risks.

Is semaglutide banned in sports?

GLP-1 medications are not currently prohibited in sport according to USADA, but semaglutide has been included in WADA’s monitoring program. Athletes should verify current rules and avoid unapproved products.

What is the biggest risk with semaglutide?

The biggest risks are using it without proper medical supervision, ignoring contraindications or warnings, and purchasing unapproved or counterfeit semaglutide products from online sellers.

Sources

Frequently asked questions

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist used in FDA-approved medications including Ozempic, Wegovy, and Rybelsus. It helps regulate blood sugar, appetite, satiety, gastric emptying, and body weight.

Is semaglutide FDA-approved?

Does semaglutide work for weight loss?

Yes. Semaglutide has strong human clinical evidence for weight loss in adults with obesity or overweight, and Wegovy is FDA-approved for chronic weight management.

Is semaglutide safe?

Semaglutide is FDA-approved for specific uses but is not risk-free. It can cause gastrointestinal side effects and carries a boxed warning related to thyroid C-cell tumors observed in rodents.

Is semaglutide banned in sports?

GLP-1 medications are not currently prohibited in sport according to USADA, but semaglutide has been included in WADA's monitoring program. Athletes should verify current rules and avoid unapproved products.

Sources

[1]
FDA: Ozempic Prescribing Information
Prescribing Information
[2]
FDA: Wegovy Prescribing Information
Prescribing Information
[3]
FDA: Rybelsus Prescribing Information
Prescribing Information
[4]
FDA: Wegovy Cardiovascular Risk Reduction Approval
Regulatory
[5]
NEJM: Once-Weekly Semaglutide in Adults with Overweight or Obesity
Clinical
[6]
PubMed: STEP 1 Trial Summary
Clinical
[7]
PubMed: Weight Regain After Semaglutide Withdrawal
Clinical
[8]
FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Regulatory Warning
[9]
USADA: Weight Loss Drugs: What Athletes Need to Know About GLP-1s
Anti Doping
[10]
USADA: 2024 WADA Prohibited List Changes
Anti Doping

Last updated May 9, 2026